Promising combo for brain metastases hits early snag: trial ends early
NCT ID NCT03765983
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested a drug called GDC-0084 combined with trastuzumab (Herceptin) in 17 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the combination could shrink or control brain tumors. Unfortunately, the trial was terminated early, so we have limited information on how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GDC-0084 and trastuzumab (Herceptin)
- What this could lead to
- If it worked, this combination could shrink or control brain metastases in HER2-positive breast cancer patients, offering a new treatment option.
- What could go wrong
- The trial was terminated early with only 17 participants, so results are very limited. It is unclear if the combination is effective or safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?